Drug intelligence / Profile preview

HXN-2003

Development stage: Preclinical
Lead developer: Earendil
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HXN-2003 is a bispecific antibody-drug conjugate (ADC) being developed by Earendil Labs (Helixon) for the treatment of colorectal cancer. It is designed to simultaneously target two tumor-associated antigens: Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (CEACAM5) and Cadherin-17 (CDH17). By binding to these two targets, the drug aims to increase tumor specificity and enhance the delivery of a cytotoxic payload directly to colorectal cancer cells, potentially reducing off-target toxicity compared to monospecific agents. As of early 2024, the program is in the discovery stage of development.

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)CDH17 (Cadherin-17)

Beyond the preview

Go deeper on HXN-2003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HXN-2003.

Explore the full profile